IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology

Phase 3 OVATION 3 Study in progress

LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN)

Dear Valued Shareholders,

A Year of Breakthroughs: IMUNON Has Never Been Stronger

As I mark my first year as President and CEO of IMUNON, I am thrilled to share the progress we have made in advancing our mission to transform cancer treatment. With robust fundamentals and groundbreaking clinical data, your company is well positioned to deliver an innovative therapy and to create significant value for you, our shareholders.

Progress with IMNN-001: A Potential Game-Changer for Ovarian Cancer

Over the past year, we have achieved remarkable milestones, most notably with our lead candidate, IMNN-001, which has entered the pivotal Phase 3 OVATION 3 Study for the frontline treatment of women newly diagnosed with advanced ovarian cancer. The Phase 2 OVATION 2 Study (n=112, median follow-up of 31 months) has demonstrated powerful and highly encouraging results, positioning IMNN-001 as a potential advance in the standard of care. Key findings, that will be presented tomorrow, June 3, in an oral presentation at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting and are also being published simultaneously in Gynecologic Oncology, include:

• Significant Survival Benefits: In the intent-to-treat (ITT) population, IMNN-001 plus standard-of-care neoadjuvant and adjuvant chemotherapy (N/ACT) extended median overall survival (OS) by 13 months (46 vs. 33 months) compared to standard-of-care N/ACT alone, with a hazard ratio of 0.69. As Dr. Premal H. Thaker, OVATION 2 Study Chair and Interim Chief of Gynecologic Oncology at Washington University School of Medicine, noted, “An increase in survival of six months is considered clinically meaningful. The data indicating that IMNN-001 could extend lives by one year or longer represent a potentially historic advance.”
  
  
• Enhanced Efficacy with PARP Inhibitors: For patients receiving poly ADP-ribose polymerase (PARP) inhibitors as maintenance therapy, median OS in the IMNN-001 arm has not yet been reached after more than five years (vs. 37 months in the control arm), with a hazard ratio of 0.38.
  
  

• Strong Results in HRD+ and BRCA Populations: Increased therapeutic activity was observed in women with homologous recombination deficiency (HRD+), including BRCA1/2 mutations, with a hazard ratio of 0.42.